- Oops!Something went wrong.Please try again later.
Shares of Infinity Pharmaceuticals (NASDAQ:INFI) decreased in after-market trading after the company reported Q4 results.
Earnings per share were up 15.00% over the past year to ($0.17), which missed the estimate of ($0.16).
Revenue of $436,000 higher by 41.56% from the same period last year, which beat the estimate of $280,000.
Infinity Pharmaceuticals hasn't issued any earnings guidance for the time being.
Infinity Pharmaceuticals hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Mar 16, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/24t7wsio
52-week high: $5.98
52-week low: $0.60
Price action over last quarter: Up 130.40%
Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments. The company operates in only one segment which is drug development.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.